83 results about "Functional impairment" patented technology

The present invention is a fully automated computer controlled system for adjustment of neurostimulation implants used in pain therapy and in treating neurological dysfunction which includes a patient interactive computer, and a universal transmitter interface integrally embedded in the patient interactive computer, or built into the antenna which is capable of stimulating any type of implanted neurostimulation devices by imitating any of the proprietary programming codes. The patient interacts with the system through the patient interactive computer (containing a unique software) which provides for consistency check of the data entered by the patient, deleting the entered data if the consistency check was not satisfactory, and requesting the patient to re-enter the data.

The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and / or using the method for smoking cessation or nicotine withdrawal.

Systems and methods for introducing one or more stimulating drugs and / or applying electrical stimulation to tissue affecting the penis to treat erectile dysfunction (for instance, following prostate surgery) uses at least one implantable system control unit (SCU) producing electrical pulses delivered via electrodes and / or producing drug infusion pulses, wherein the stimulating drug(s) are delivered via one or more pumps and infusion outlets.

A single, integrated device in which a body fluid (e.g., blood) of a human or animal can be both collected and analyzed easily and without risk of contamination is disclosed. The collection portion and analysis portion of the device are permanently joined to permit movement of small quantities of body fluid under controlled conditions, to minimize any waste of the body fluid, to ensure that no contamination reaches the main body fluid volume, and to create a permanent physical record of the results of the analysis in association with the fluid sample itself: A wide variety of different body fluid components which may be indicative of various diseases, dysfunctions and abnormalities of the human or animal or the body fluid itself can be tested for. The device includes a container for collecting human or animal body fluid, one or more testing chambers containing one or more analysis units activated by body fluid; a transfer pump or vacuum assembly to transfer one or more samples into the analysis units; and one-way valves or the equivalent to prevent any portion of the withdrawn sample from being returned to the collection container. The body fluid acted upon may be blood, blood plasma, urine, bile, pleural fluid, ascites fluid, stomach or intestine fluid, colostrom, milk or lymph.

In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for oral mucositis; digestive mucositis; esophageal mucositis; intestinal mucositis). In alternative embodiments, the invention provides cytoprotection products that may be used either alone or in combination with other medical therapies such as cancer chemotherapies and radiation therapies.

A method for isolating and quantifying impairments of a subject's gaze stabilization system is provided. A subject's static visual acuity is measured to arrive at an assessment. The subject's visual acuity is then measured when the subject's head is moving and a display object is fixed to arrive at a first dynamic measurement. The subject's visual acuity is also measured when the subject's head is fixed and the display object is moving to arrive at a second dynamic measurement. The assessment and the first and second dynamic measurements are then used to determine an impairment of the subject's gaze stabilization system.

This invention relates to compounds of formula Itheir use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye. Also disclosed are methods for intravitreal delivery of therapeutic gene constructs to retinal neuron cells, and specifically to ON bipolar cells, of the mammalian eye, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and / or in vivo applications including the treatment of retinitis pigmentosa, melanoma-associated retinopathy, and congenital stationary night blindness.

This invention relates to compounds of formula Itheir use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

This invention relates to compounds of formula Itheir use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

This invention relates to compounds of formula Itheir use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and / or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

A method is presented to address quantitative assessment of functional impairment in a subject, where the method comprises the steps of: (1) presenting a plurality of tests to a subject on a display, the plurality of tests comprising a series of scenes, the scene comprising at least one stimulus, wherein the scene may be associated with visual, auditory, and tactile stimulus arrays; (2) modulating at least one spatial characteristic of at least one stimulus; (3) receiving feedback from the subject via at least one input device; (4) quantitatively refining the scene relative to the received feedback; (5) calculating the relationship between at least one of the scene, the stimulus, and the quantitatively refined scene; (6) adjusting the scene relative to the calculated relationship; (7) determining equilibrated scene parameter of the subject; (8) recording the equilibrated scene parameter onto a tangible computer readable medium; (9) generating at least one diagnosis to the functional impairment associated with the equilibrated scene parameter; (10) recommending at least one treatment to the subject. An apparatus for quantitative assessment of functional impairment in a subject comprising an input device, a display device, a control device, and a tangible computer readable medium. A quantitative assessment profile of functional impairment by continuous modulation of specific perceptual domains on a stimulus and generating psychophysical responses on a tangible computer readable medium.

An alkyl ether derivative represented by the formula: wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

A low-oscillation and space-saving drive for a changeable format folder of a rotary printing is provided, the rotary printing machine having rotating subassemblies that can be driven, in particular a cutting cylinder, a pin folding blade cylinder, a folding jaw cylinder, a gripper folding blade cylinder, and perforating cylinders belonging to a perforating device. The drive is split up into individual subsystems, and each subsystem is assigned a controlled-position drive motor. In the event of failure of a drive motor, the drive continues to operate without functional impairment.

Drug compositions containing a substituted diamine compound represented by formula (1):Q1-Q2-r-N(R1)-Q3-N(R2)  (1)wherein Q3 represents the following groupwherein Q5 represents an alkylene group having 4 carbon atoms, R3 represents a hydrogen atom, and R4 represents a 3-6 membered heterocyclic group which may be substituted; are useful for preventing and / or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

The present invention provides compounds of formula I described herein. The present invention also provides a method of treating a cognitive dysfunction in a mammal. The method includes administering to the mammal an effective amount of a compound of formula I described herein (e.g., stearyl choline chloride).

The invention discloses certain steroidal sapogenins and derivatives thereof, and their use in the treatment of cognitive dysfunction, non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, and receptor loss in the absence of cognitive, neural and neuromuscular impairment. Methods of synthesis, treatment and pharmaceutical compositions are also disclosed.

Methods of using amino acid precursors of the serotonin and catecholamine neurotransmitter systems and laboratory urinary assay of serotonin and catecholamine neurotransmitter levels for optimal treatment of neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and / or catecholamine neurotransmitter systems. The methods may also include determining a urinary neurotransmitter phase response to a change in dosing of supplemental amino acid precursors of the serotonin and catecholamine neurotransmitters to optimally treat neurotransmitter dysfunction and dysfunction of systems regulated or controlled by the serotonin and / or catecholamine neurotransmitter systems.

A low-oscillation and space-saving drive for a changeable format folder of a rotary printing is provided, the rotary printing machine having rotating subassemblies that can be driven, in particular a cutting cylinder, a pin folding blade cylinder, a folding jaw cylinder, a gripper folding blade cylinder, and perforating cylinders belonging to a perforating device. The drive is split up into individual subsystems, and each subsystem is assigned a controlled-position drive motor. In the event of failure of a drive motor, the drive continues to operate without functional impairment.

The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.

The invention relates to a piston pump (10) for supplying a pressure medium to at least one vehicle brake, a main cylinder, a pressure medium container, or a pressure medium store, of a regulated vehicle brake installation. The aim of the invention is to enable a piston pump (10) joined to a structural unit to be integrated into a receiving body (3) in a simple manner and in such a way that the construction space is reduced. The invention also aims to keep valve seats (38, 54) of check valves (32,33,36,37) as free as possible from pressing or fixing forces, in order to prevent the deformation or functional impairment thereof. To this end, a sleeve (18,19) has a radial flange for fixing between the closing element (52) and the receiving body (3).

A prosthetic device is controlled based on measured electrical signals corresponding to muscle activity in a lower-extremity anatomical analog to a dysfunctional or absent portion of an upper extremity of an individual. In particular, an activity monitoring device measures electrical signals corresponding to muscle activity in the lower-extremity anatomical analog. Then, a communication device communicates information specifying the electrical signals to a pattern-recognition device. The pattern-recognition device identifies a natural mode of movement of the lower-extremity anatomical analog based on the information. For example, the natural mode of movement may be identified using a pattern-recognition technique. Next, the pattern-recognition device provides a control signal to a prosthetic device associated with the dysfunctional or absent portion of the upper extremity, where the control signal specifies a natural mode of movement of the prosthetic device that is an analog to the natural mode of movement of the lower-extremity anatomical analog.

Current medication labels are very difficult for people with disabilities, language barriers, functional impairments, or illiteracy to read, potentially increasing the risk for accidental medication overdoses and / or poor compliance with medication administration and adherence. By having a color coded sticker system with an enclosed full body guide in the form of a poster, and a home health medication record card, these stickers are placed on each medication bottle as a symbol for what the medication is used for. The stickers are color coded in order to distinguish the time the medication is to be administered. Home health agencies may use the poster and stickers as they educate their patients about the medications they take.